ACTRN12619000177156招募中2 期
A Phase 2, Multi-centeR, Randomized, DoUBle-Masked, Placebo-Controlled StudY to Evaluate the Clinical Safety and Efficacy of OKG-0301 in the Treatment of Acute Adenoviral Conjunctivitis (RUBY)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 219
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Each patient MUST:
- •1.Be willing and able to provide informed consent either written, or if the patient is not able to read, provide consent as stipulated by local laws and Human Research Ethics Committee (HREC) guidelines.
- •2.Be willing and able to follow all instructions and attend all study visits.
- •3.Have a clinical diagnosis of suspected acute adenoviral conjunctivitis in at least 1 eye and the presence of both of the following minimal clinical signs in that same eye:
- •Bulbar conjunctival redness: a minimum grade of ‘1’ on 0-3 scale
- •Watery ocular discharge: a minimum grade of ‘1’ on a 0-3 scale
- •4.Patient reported presence of signs and symptoms consistent with adenoviral conjunctivitis equal to or less than 3 days in same eye prior to Visit 1.
- •5.Have a positive AdenoPlus® test at Visit 1 in the same eye that meets the minimum 1+ grade for bulbar conjunctival redness and watery ocular discharge.
- •6.Be willing to discontinue contact lens wear for the duration of the study.
排除标准
- •Each patient MUST NOT:
- •1.Have known sensitivity or poor tolerance to any component of the study medications or diagnostics.
- •2.Have a history of ocular surgical intervention or trauma within 12 weeks prior to Visit 1 or planned for the period of the study.
- •3.Have presence of any active ocular inflammation (e.g., uveitis, allergic conjunctivitis, ocular rosacea, or iritis), other than acute adenoviral conjunctivitis.
- •4.Have clinical signs or presence of an ocular infection other than acute adenoviral conjunctivitis (e.g., bacterial, fungal or other ocular viral infection, such as herpes).
- •5.Have the presence of corneal subepithelial infiltrates at baseline.
- •6.Have a history of recurrent corneal erosion syndrome, ulcerative keratitis or dry eye, including meibomian gland dysfunction and other ocular surface diseases.
- •7.Have presence of blepharitis, lid abnormality, significant inflammation of the lid margin, or ptosis.
- •8.Have lacrimal duct obstruction in either eye.
- •9.Have presence of any other clinically significant findings during the slit lamp exam that may interfere with study parameters or otherwise confound the data as determined by the investigator
- •10.Have any clinically significant retinal or optic nerve findings (as observed in the non-dilated fundus exam) or prior diagnoses in either eye that may interfere with study parameters or otherwise confound the data as determined by the investigator).
- •11.Have used any topical ocular or systemic anti-viral or topical ocular or systemic corticosteroid within 7 days of enrollment and do not plan to start any topical ocular or systemic anti-viral during study duration. Inhaled, intranasal, and topical dermatologic steroids (except on the face) are allowed during the study.
- •12.Initiate or continue the use of warm or cold compresses for the duration of the trial.
- •13.Have used any topical ophthalmic solutions, including tear substitutes and diagnostics, within 2 hours of Visit 1 and be unable to discontinue all topical ophthalmic solutions (including diagnostics, except as required by this protocol and antibiotics) for the duration of the study. In addition, if the patient has used an artificial tear or other topical ophthalmic formulated in a hydrogel within the past 72 hours.
- •14.Be currently pregnant, nursing, or planning a pregnancy; or be a woman that has a positive pregnancy test.
- •15.Have any uncontrolled (not on a stable regimen for the past 30 days) systemic disease or debilitating disease (e.g., cardiovascular disease, hypertension, diabetes, or cystic fibrosis) or taking medications known to impact the ocular surface and/or tear film.
- •16.Have a planned overnight hospitalization during the period of the study.
- •17.Have any uncontrolled (not on a stable regimen for the past 30 days) autoimmune disease or taking medications known to impact the ocular surface and/or tear film.
- •18.Have prior (within 30 days of beginning study treatment) or anticipated concurrent use of an investigational drug or device.
- •19.Have a condition or a situation which, in the investigator’s opinion, may put the patient at increased risk, confound study data, or interfere significantly with the patient’s study participation.
- •20.Be unlikely to follow study instructions or to complete all required study visits or has a condition or situation that in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly
研究者
相似试验
进行中（未招募）
1 期
Evaluation of the safety and efficacy of PAD ciclosporin in dry eye patientsocular dryness (Dry Eye Disease - DED)MedDRA version: 21.1Level: LLTClassification code 10013778Term: Dry eyesSystem Organ Class: 100000004853MedDRA version: 21.1Level: LLTClassification code 10013777Term: Dry eye syndromeSystem Organ Class: 100000004853EUCTR2015-000937-54-DKMC2 Therapeutics Ltd.264
进行中（未招募）
1 期
Evaluation of the safety and efficacy of PAD ciclosporin in dry eye patientsocular dryness (Dry Eye Disease - DED)MedDRA version: 21.1Level: LLTClassification code 10013778Term: Dry eyesSystem Organ Class: 100000004853MedDRA version: 21.1Level: LLTClassification code 10013777Term: Dry eye syndromeSystem Organ Class: 100000004853EUCTR2015-000937-54-PTDRUG DELIVERY SOLUTIONS ApS (PART OF MC2 BIOTEK GROUP)263
进行中（未招募）
1 期
Evaluation of the safety and efficacy of PAD ciclosporin in dry eye patientsocular dryness (Dry Eye Disease - DED)MedDRA version: 20.0Level: LLTClassification code 10013778Term: Dry eyesSystem Organ Class: 100000004853MedDRA version: 20.0Level: LLTClassification code 10013777Term: Dry eye syndromeSystem Organ Class: 100000004853EUCTR2015-000937-54-ATDRUG DELIVERY SOLUTIONS ApS (PART OF MC2 BIOTEK GROUP)264
进行中（未招募）
1 期
Evaluation of the safety and efficacy of PAD ciclosporin in dry eye patientsocular dryness (Dry Eye Disease - DED)MedDRA version: 18.0Level: LLTClassification code 10013778Term: Dry eyesSystem Organ Class: 100000004853MedDRA version: 18.0Level: LLTClassification code 10013777Term: Dry eye syndromeSystem Organ Class: 100000004853EUCTR2015-000937-54-NODRUG DELIVERY SOLUTIONS ApS (PART OF MC2 BIOTEK GROUP)263
进行中（未招募）
1 期
Evaluation of the safety and efficacy of PAD ciclosporin in patients with dry eye diseaseEUCTR2015-000937-54-CZDRUG DELIVERY SOLUTIONS ApS264